Bevacizumab-based Chemotherapy for Poorly-differentiated Neuroendocrine Tumors.

Date publication

octobre 2018

Journal

Anticancer research

Auteurs

Membres identifiés du Cancéropôle Est :
Pr GHIRINGHELLI François , Dr VINCENT Julie , Dr BENGRINE-LEFEVRE Leila , Dr FUMET Jean-David

Tous les auteurs :
Collot T, Fumet JD, Klopfenstein Q, Vincent J, Bengrine L, Ghiringhelli F

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/30275226

Résumé

To assess and report the efficacy of and tolerance to bevacizumab-based chemotherapy in treatment outcome of metastatic poorly differentiated neuroendocrine tumors.

Mots clés

Metastatic poorly differentiated neuroendocrine tumor, bevacizumab, chemotherapy, retrospective study

Référence

Anticancer Res.. 2018 Oct;38(10):5963-5968